Stockscreener 앱 받기
1.79
0.00%
0.00
시장 영업 전:
1.69
-0.10
-5.59%
Vigil Neuroscience Inc 주식(VIGL)의 최신 뉴스
Vigil Neuroscience (NASDAQ:VIGL) Upgraded at William Blair - Defense World
Vigil Neuroscience stock hits 52-week low at $1.43 - Investing.com Australia
Vigil Neuroscience stock hits 52-week low at $1.43 By Investing.com - Investing.com South Africa
Vigil Neuroscience Presents Data on its Small Molecule - GlobeNewswire
Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials By Investing.com - Investing.com South Africa
Vigil presents data on oral small molecule program including VG-3927 - TipRanks
Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials - Investing.com
Clinical Data Breakthrough: Vigil's New Alzheimer's Drug Targets Both Aβ and Tau Pathologies - Stock Titan
Vigil Neuroscience Reports 2024 Results and Clinical Progress - TipRanks
Vigil Neuroscience Files Secondary Stock Shelf - MarketScreener
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Decline in Short Interest - Defense World
Vigil Neuroscience (VIGL) to Release Earnings on Tuesday - Defense World
H.C. Wainwright cuts Vigil Neuroscience stock target to $14 By Investing.com - Investing.com Canada
Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
H.C. Wainwright cuts Vigil Neuroscience stock target to $14 - Investing.com India
FY2029 Earnings Forecast for VIGL Issued By Wedbush - Defense World
Q1 Earnings Estimate for VIGL Issued By William Blair - Defense World
HC Wainwright Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World
Wedbush Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World
Vigil Neuroscience Inc.: Promising Biomarker Data and Strategic Advancements Justify Buy Rating - TipRanks
Wedbush Cuts Price Target on Vigil Neuroscience to $13 From $24, Keeps Outperform Rating - Marketscreener.com
Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com Australia
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com India
Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data - Investing.com
Stifel maintains Buy on Vigil Neuroscience, target at $11 - Investing.com
Vigil Neuroscience, Inc. SEC 10-K Report - TradingView
Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq
Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq
Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire
Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan
SPY ETF News, 3/13/2025 - The Globe and Mail
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire
Vigil Neuroscience To Present At The Stifel 2025 Virtual CNS Forum - MENAFN.COM
Exclusive CNS Forum: Vigil Neuroscience Reveals Latest Breakthroughs in Neurodegeneration Treatment - StockTitan
Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely? - Yahoo Finance
Best Stock to Buy Right Now: Dutch Bros vs. Starbucks - The Globe and Mail
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6% - Defense World
Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Insider Monkey
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire
What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat
0.24%
36.06%
자본화:
|
볼륨(24시간):